Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes.

摘要: Antipsychotic-induced movement disorders are major side effects of antipsychotic drugs among schizophrenia patients, and include antipsychotic-induced parkinsonism (AIP) tardive dyskinesia (TD). Substantial pharmacogenetic work has been done in this field, several susceptibility variants have suggested. In paper, the genetics is considered a broader context. We hypothesize that genetic risk factors for AIP TD may provide insights into pathophysiology Parkinson's disease (PD). Since loss dopaminergic stimulation (albeit pharmacological degenerative PD) shared by two clinical entities, genes associated with to be modifier influence expression PD sub-phenotypes, such as age at onset, severity or rate progression. This due their possible functional on compensatory mechanisms striatal dopamine loss. Better potential might beneficial early later stages course. vulnerability also related latent impairment nigrostriatal pathway, affecting its functionality, leading subclinical deficits striatum. Susceptibility patients development L-dopa induced (LID), an additional relevant sub-phenotype. LID share common background TD, which it shares features. Genetic predispose both phenotypes, exerting pleiotropic effect. According hypothesis, elucidating advance our understanding multiple aspects course, rendering potentially rewarding field study.